These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18775980)

  • 1. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.
    Bruin GJ; Faller T; Wiegand H; Schweitzer A; Nick H; Schneider J; Boernsen KO; Waldmeier F
    Drug Metab Dispos; 2008 Dec; 36(12):2523-38. PubMed ID: 18775980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human.
    Weiss HM; Fresneau M; Camenisch GP; Kretz O; Gross G
    Drug Metab Dispos; 2006 Jun; 34(6):971-5. PubMed ID: 16531476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of deferasirox.
    Tanaka C
    Clin Pharmacokinet; 2014 Aug; 53(8):679-94. PubMed ID: 24996374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
    Miyazawa K; Ohyashiki K; Urabe A; Hata T; Nakao S; Ozawa K; Ishikawa T; Kato J; Tatsumi Y; Mori H; Kondo M; Taniguchi J; Tanii H; Rojkjaer L; Omine M
    Int J Hematol; 2008 Jul; 88(1):73-81. PubMed ID: 18597054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferasirox: A comprehensive drug profile.
    Kabil MF; Nasr M
    Profiles Drug Subst Excip Relat Methodol; 2024; 49():1-18. PubMed ID: 38423705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.
    Galanello R; Piga A; Cappellini MD; Forni GL; Zappu A; Origa R; Dutreix C; Belleli R; Ford JM; Rivière GJ; Balez S; Alberti D; Séchaud R
    J Clin Pharmacol; 2008 Apr; 48(4):428-35. PubMed ID: 18281442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
    Maker GL; Siva B; Batty KT; Trengove RD; Ferrari P; Olynyk JK
    Nephrology (Carlton); 2013 Mar; 18(3):188-93. PubMed ID: 23332024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
    Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
    Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.
    Sechaud R; Robeva A; Belleli R; Balez S
    Int J Clin Pharmacol Ther; 2008 Oct; 46(10):519-26. PubMed ID: 18826866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
    Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
    Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of a low dose of 14C-bisphenol A in male rats and its main biliary excretion as BPA glucuronide.
    Kurebayashi H; Betsui H; Ohno Y
    Toxicol Sci; 2003 May; 73(1):17-25. PubMed ID: 12700409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chelation of aluminum by combining deferasirox and deferiprone in rats.
    Saljooghi AS
    Toxicol Ind Health; 2012 Sep; 28(8):740-5. PubMed ID: 22025507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
    Allegra S; De Francia S; Cusato J; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2016 Nov; 68(11):1417-1421. PubMed ID: 27672004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?
    Mattioli F; Puntoni M; Marini V; Fucile C; Milano G; Robbiano L; Perrotta S; Pinto V; Martelli A; Forni GL
    Eur J Haematol; 2015 Apr; 94(4):310-7. PubMed ID: 25081908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
    Kontoghiorghes GJ
    Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.